Abbaskhanian A, Ehteshami S, Sajjadi S, Rezai MS. Effects of piracetam on pediatric breath holding spells: a randomized double blind controlled trial. Iran J Child Neurol. 2012;6(4):9-15. View abstract.

Ackerman PT, Dykman RA, Holloway C, et al. A trial of piracetam in two subgroups of students with dyslexia enrolled in summer tutoring. J Learn Disabil. 1991;24(9):542-9. View abstract.

Akhondzadeh S, Tajdar H, Mohammadi MR, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev. 2008;39(3):237-45. View abstract.

Al Hajeri A, Fedorowicz Z. Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database Syst Rev. 2016 Feb 12;2:CD006111. View abstract.

Arhami Dolatabadi A, Larimi SR, Safaie A. Oral piracetam vs betahistine in outpatient management of peripheral vertigo; a randomized clinical trial. Arch Acad Emerg Med. 2019;7(1):e9. View abstract.

Barkat K, Ahmad M, Minhas MU, et al. Development of a simple chromatographic method for the determination of piracetam in human plasma and its pharmacokinetic evaluation. Drug Res (Stuttg). 2014;64(7):384-8. View abstract.

Chen SY, Liu JW, Wang YH, et al. The conditions under which piracetam is used and the factors that can improve National Institute of Health stroke scale score in ischemic stroke patients and the importance of previously unnoticed factors from a hospital-based observational study in Taiwan. J Clin Med. 2019;8(1). pii: E122. View abstract.

Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer’s disease. Neurology. 1993;43(2):301-5. View abstract.

De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam-its use in the treatment of acute stroke. Pharmacopsychiatry. 1999;32 Suppl 1:33-7. View abstract.

Dezena RMB, Antunes NJ, Campos R, et al. Pharmacodynamic evaluation of L-carnitine and piracetam in muscle injury induced by the chronic use of simvastatin. Int J Clin Pharmacol Ther 2020;58(9):482-490. View abstract.

Di Ianni M, Wilsher CR, Blank MS, et al. The effects of piracetam in children with dyslexia. J Clin Psychopharmacol. 1985;5(5):272-8. View abstract.

Dogan NÖ, Avcu N, Yaka E, et al. Comparison of the therapeutic efficacy of intravenous dimenhydrinate and intravenous piracetam in patients with vertigo: a randomised clinical trial. Emerg Med J. 2015;32(7):520-4. View abstract.

Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatr Neurol. 1998;18(1):41-5.

El-Hazmi MA, Al-Fawaz I, Warsy A, et al. Piracetam for the treatment of sickle cell disease in children- a double blind test. Saudi Med J. 1998;19(1):22-27. View abstract.

Fang Y, Qiu Z, Hu W, et al. Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis. Exp Ther Med 2014;7(2):429-434. View abstract.

Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58(5):781-6. View abstract.

Ghazavi MR, Salehi MM, Nasiri J, Yaghini O, Mansouri V, Hoseini N. The comparison of levetiracetam and piracetam effectiveness on breath-holding spells in children: a randomized controlled clinical trial. Adv Biomed Res. 2021 Dec 25;10:47. View abstract.

Grotemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. J Neurol Sci. 2000;181(1-2):65-72. View abstract.

Holinski S, Claus B, Alaaraj N, et al. Cerebroprotective effect of piracetam in patients undergoing open heart surgery. Ann Thorac Cardiovasc Surg 2011;17(2):137-42. View abstract.

Hussain Y, Krishnamurthy S. Piracetam attenuates binge eating disorder related symptoms in rats. Pharmacol Biochem Behav. 2018;169:35-47. View abstract.

Kampman K, Majewska MD, Tourian K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003;28(3):437-48. View abstract.

Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998;64(3):344-8. View abstract.

Libov I, Miodownik C, Bersudsky Y, et l. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68(7):1031-7. View abstract.

Lobaugh NJ, Karaskov V, Rombough V, et al. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch Pediatr Adolesc Med 2001;155(4):442-8. View abstract.

Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 2010;70(3):287-312. View abstract.

Mateo D, Giménez-Roldán S. The effect of piracetam on involuntary movements in Huntington’s disease. A double-blind, placebo-controlled study. Neurologia. 1996;11(1):16-9. View abstract.

May BH, Yang AW, Zhang AL, et al. Chinese herbal medicine for mild cognitive impairment and age associated memory impairment: a review of randomised controlled trials. Biogerontology 2009;10(2):109-23.

Mikati MA, Solh HM, Deryan DE, Sahli IF, Dabbous IA. A preliminary report on piracetam in sickle cell anemia: A double-blind crossover clinical trial and effects on erythrocyte survival. The King Faisal Spec Hosp J 1983;3:233-234.

Moriau M, Crasborn L, Lavenne-Pardonge E, et al. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung. 1993;43(2):110-8. View abstract.

Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009;39(3):311-21. View abstract.

Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1999;24(5):369-74. View abstract.

Ozdemir H, Akinci E, Coskun F. Comparison of the effectiveness of intravenous piracetam and intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department. Singapore Med J 2013;54(11):649-52. View abstract.

Psillas G, Pavlidis P, Karvelis I, et al. Potential efficacy of early treatment of acute acoustic trauma with steroids and piracetam after gunshot noise. Eur Arch Otorhinolaryngol. 2008;265(12):1465-9. View abstract.

Rameis H, Hitzenberger G, Kutscher R, Manigley C. Pharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal elimination. Int J Clin Pharmacol Ther. 1994;32(9):458-65. View abstract.

Rao MG, Holla B, Varambally S, et al. Piracetam treatment in patients with cognitive impairment. Gen Hosp Psychiatry. 2013;35(4):451.e5-6. View abstract.

Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000419. View abstract.

Rosenhall U, Deberdt W, Friberg U, Kerr A, Oosterveld W. Piracetam in patients with chronic vertigo. Clin. Drug Invest. 1996;11(5):251-60.

Sandyk R, Gillman MA. Piracetam causes confusion in a patient with temporal lobe epilepsy. J Am Geriatr Soc. 1985;33(4):305. View abstract.

Sano M, Stern Y, Marder K, Mayeux R. A controlled trial of piracetam in intellectually impaired patients with Parkinson’s disease. Mov Disord. 1990;5(3):230-4. View abstract.

Szalma I, Kiss A, Kardos L, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg 2006;82(4):1430-5. View abstract.

Tang WK, Ungvari GS, Leung HC. Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study. J ECT. 2002;18(3):130-7. View abstract.

Tuncer S, Sencan A, Aral M, Ayhan S. Piracetam-induced dysarthria: an unusual complication of antithrombotic prophylaxis after toe to finger transfer. J Reconstr Microsurg. 2011;27(9):575-6. View abstract.

Waegemans T, Wilsher CR, Danniau A, et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 2002;13(4):217-24. View abstract.

Washington N, Harris M, Mussellwhite A, Spiller RC. Moderation of lactulose-induced diarrhea by psyllium: effects on motility and fermentation. Am J Clin Nutr 1998;67:317-21. View abstract.

Waters B, Resnick M, Simeon J, et al. An adverse reaction to piracetam in an hypothyroid 10 year old boy. Prog Neuropsychopharmacol. 1980;4(2):207-9. View abstract.

Wilsher CR, Bennett D, Chase CH, et al. Piracetam and dyslexia: effects on reading tests. J Clin Psychopharmacol 1987;7(4):230-7. View abstract.

Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-82. View abstract.

Winnicka K, Tomasiak M, Bielawska A. Piracetam-an old drug with novel properties? Acta Pol Pharm. 2005;62(5):405-9. View abstract.

Yeo SH, Lim ZI, Mao J, Yau WP. Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2017 Jul 29. View abstract.

Zhang J, Wei R, Chen Z, Luo B. Piracetam for aphasia in post-stroke patients: A systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(7):575-87. View abstract.

Zongfang Z, Wenjing L, Zhaomin C, Lei Z. Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction. Pak J Pharm Sci 2020;33(5(Special)):2405-2411. View abstract.